Glycolipid binding preferences of shiga toxin variants

PLoS ONE

Volumn 9, Issue 7, 2014, Pages

  Karve, Sayali S ^a   Weiss, Alison A ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLOBOTETRAOSYLCERAMIDE; GLOBOTRIAOSYLCERAMIDE; SHIGA TOXIN; SHIGA TOXIN 2A; SHIGA TOXIN 2B; SHIGA TOXIN 2C; SHIGA TOXIN 2D; SPHINGOLIPID; UNCLASSIFIED DRUG; CERAMIDE; GLYCOLIPID;

ALPHA CHAIN; AMINO ACID SEQUENCE; ARTICLE; BETA CHAIN; BINDING AFFINITY; CELL MEMBRANE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; NUCLEOTIDE SEQUENCE; PROTEIN STABILITY; RECEPTOR BINDING; SEQUENCE ALIGNMENT; UPREGULATION; CHEMISTRY; CONFORMATION; ISOLATION AND PURIFICATION; METABOLISM; MOLECULAR GENETICS; SEQUENCE HOMOLOGY;

AMINO ACID SEQUENCE; CERAMIDES; ENZYME-LINKED IMMUNOSORBENT ASSAY; GLYCOLIPIDS; MOLECULAR CONFORMATION; MOLECULAR SEQUENCE DATA; SEQUENCE HOMOLOGY, AMINO ACID; SHIGA TOXIN;

EID: 84903698149     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0101173     Document Type: Article

References (54)

1. Pina DG, Stechmann B, Shnyrov VL, Cabanie L, Haicheur N, et al. (2008) Correlation between Shiga toxin B-subunit stability and antigen crosspresentation: a mutational analysis. FEBS letters 582: 185-189.
2. Collins CG, (2010) A review of the pathophisiology and treatment of Shiga toxin producing E. coli infection. Pract Gastroenterol: 41-50.
3. Tilden J, Young W, McNamara AM, Custer C, Boesel B (1996) A new route of transmission for Escherichia coli: Infection from dry fermented salami. American Journal of Public Health 86: 1142-1145. (Pubitemid 26271542)
4. MacDonald IA, Gould IM and Curnow J (1996) Epidemiology of infection due to Escherichia coli O157: a 3-year prospective study. Epidemiol Infect 116: 279-284. (Pubitemid 26191040)
5. Slutsker L, Ries AA, Greene KD, Wells JG, Hutwagner L, et al. (1997) Escherichia coli O157: H7 Diarrhea in the United States: Clinical and Epidemiologic Features. Annals of Internal Medicine 126: 505-513. (Pubitemid 27143628)
6. Torgersen ML, Engedal N, Pedersen AM, Husebye H, Espevik T, et al. (2011) Toll-like receptor 4 facilitates binding of Shiga toxin to colon carcinoma and primary umbilical vein endothelial cells. FEMS immunology and medical microbiology 61: 63-75.
7. Carter AO, Borczyk AA, Carlson JAK, Harvey B, Hockin JC, et al. (1987) A Severe Outbreak of Escherichia coli O157:H7-Associated Hemorrhagic Colitis in a Nursing Home. New England Journal of Medicine 317: 1496-1500. (Pubitemid 17160544)
8. Rowe PC, Lior H, Wells GA, McLaine PN (1993) Diarrhoea in close contacts as a risk factor for childhood haemolytic uraemic syndrome. Epidemiol Infect 110: 9-16. (Pubitemid 23217323)
9. Gould LH, Demma L, Jones TF, Hurd S, Vugia DJ, et al. (2009) Hemolytic uremic syndrome and death in persons with Escherichia coli O157:H7 infection, foodborne diseases active surveillance network sites, 2000-2006. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America 49: 1480-1485.
10. Obrig TG (2010) Escherichia coli Shiga Toxin Mechanisms of Action in Renal Disease. Toxins 2: 2769-2794.
11. Trachtman H, Austin C, Lewinski M and Stahl RA (2012) Renal and neurological involvement in typical Shiga toxin-associated HUS. Nature reviews Nephrology 8: 658-669.
12. Zoja C, Buelli S and Morigi M (2010) Shiga toxin-associated hemolytic uremic syndrome: pathophysiology of endothelial dysfunction. Pediatric nephrology 25: 2231-2240.
13. Bitzan M (2009) Treatment options for HUS secondary to Escherichia coli O157:H7. Kidney international Supplement: S62-66.
14. Fraser ME, Fujinaga M, Cherney MM, Melton-Celsa AR, Twiddy EM, et al. (2004) Structure of shiga toxin type 2 (Stx2) from Escherichia coli O157:H7. The Journal of biological chemistry 279: 27511-27517. (Pubitemid 38812591)
15. Fraser ME, Chernaia MM, Kozlov YV and James MN (1994) Crystal structure of the holotoxin from Shigella dysenteriae at 2.5 A h resolution. Nat Struct Biol 1: 59-64. (Pubitemid 24974781)
16. Saxena SK, O'Brien AD and Ackerman EJ (1989) Shiga toxin, Shiga-like toxin II variant, and ricin are all single-site RNA N-glycosidases of 28 S RNA when microinjected into Xenopus oocytes. J Biol Chem 264: 596-601. (Pubitemid 19027648)
17. Donohue-Rolfe A, Keusch GT, Edson C, Thorley-Lawson D and Jacewicz M (1984) Pathogenesis of Shigella diarrhea. IX. Simplified high yield purification of Shigella toxin and characterization of subunit composition and function by the use of subunit-specific monoclonal and polyclonal antibodies. J Exp Med 160: 1767-1781. (Pubitemid 15194002)
18. Endo YT, Yutsudo T, Takeda Y, Ogasawara T, et al. (1988) Site of action of a Vero toxin (VT2) from Escherichia coli O157:H7 and of Shiga toxin on eukaryotic ribosomes. RNA N-glycosidase activity of the toxins. Eur J Biochem 171: 45-50. (Pubitemid 18042873)
19. Melton-Celsa A, Mohawk K, Teel L and O'Brien A (2012) Pathogenesis of Shiga-toxin producing escherichia coli. Current topics in microbiology and immunology 357: 67-103.
20. O'Brien A (1992) Shiga toxin: biochemistry, genetics, mode of action, and role in pathogenesis. Current topics in microbiology and immunology 180: 65-94.
21. Ethelberg S, Olsen KE, Scheutz F, Jensen C, Schiellerup P, et al. (2004) Virulence factors for hemolytic uremic syndrome, Denmark. Emerg Infect Dis 10: 842-847. (Pubitemid 38552751)
22. Boerlin P, McEwen MA, Boerlin-Petzold F, Wilson JB, Johnson RP, et al. (1999) Associations between virulence factors of Shiga toxin-producing Escherichia coli and disease in humans. J Clin Microbiol 37: 497-503. (Pubitemid 29091254)
23. Kawano K, Okada M, Haga T, Maeda K and Goto Y Relationship between pathogenicity for humans and stx genotype in Shiga toxin-producing Escherichia coli serotype O157. Eur J Clin Microbiol Infect Dis 27: 227-232.
24. Orth D, Grif K, Khan AB, Naim A, Dierich MP, et al. (2007) The Shiga toxin genotype rather than the amount of Shiga toxin or the cytotoxicity of Shiga toxin in vitro correlates with the appearance of the hemolytic uremic syndrome. Diagn Microbiol Infect Dis 59: 235-242. (Pubitemid 350016692)
25. Ostroff SM, Tarr PI, Neill MA, Lewis JH, Hargrett-Bean N, et al. Toxin genotypes and plasmid profiles as determinants of systemic sequelae in Escherichia coli O157:H7 infections. J Infect Dis 160: 994-998.
26. Strockbine NA, Marques LR, Newland JW, Smith HW, Holmes RK, et al. (1986) Two toxin-converting phages from Escherichia coli O157:H7 strain 933 encode antigenically distinct toxins with similar biologic activities. Infect Immun 53: 135-140. (Pubitemid 16084376)
27. Fuller CA, Pellino CA, Flagler MJ, Strasser JE and Weiss AA (2011) Shiga toxin subtypes display dramatic differences in potency. Infection and immunity 79: 1329-1337.
28. Head SC, Karmali MA and Lingwood CA (1991) Preparation of VT1 and VT2 hybrid toxins from their purified dissociated subunits. evidence for B subunit modulation of a subunit function. J Biol Chem 266: 3617-3621. (Pubitemid 21909257)
29. Marcato P, Vander Helm K, Mulvey GL and Armstrong GD (2003) Serum Amyloid P Component Binding to Shiga Toxin 2 Requires Both A Subunit and B Pentamer. Infection and immunity 71: 6075-6078. (Pubitemid 37205665)
30. Weinstein DL, Jackson MP, Perera LP, Holmes RK and O'Brien AD (1989) In vivo formation of hybrid toxins comprising Shiga toxin and the Shiga-like toxins and role of the B subunit in localization and cytotoxic activity. Infect Immun 57: 3743-3750. (Pubitemid 20001242)
31. Karmali MA (1994) Recent advances in verocytotoxin-producing Escherichia coli infections. Elsevier Science. 245-248 p.
32. Flagler MJ, Mahajan SS, Kulkarni AA, Iyer SS and Weiss AA (2010) Comparison of binding platforms yields insights into receptor binding differences between shiga toxins 1 and 2. Biochemistry 49: 1649-1657.
33. Jacewicz M, Clausen H, Nudelman E, Donohue-Rolfe A and Keusch GT (1986) Pathogenesis of Shigella diarrhea. XI. isolation of a shigella toxin-binding glycolipid from rabbit jejunum and HeLa cells and its identification as globotriaosylceramide. J Exp Med 163: 1391-1404. (Pubitemid 16043460)
34. Tyrrell GJ, Ramotar K, Toye B, Boyd B, Lingwood CA, et al. (1992) Alteration of the carbohydrate binding specificity of verotoxins from Gal alpha 1-4Gal to GalNAc beta 1-3Gal alpha 1-4Gal and vice versa by site-directed mutagenesis of the binding subunit. Proc Natl Acad Sci USA 89: 524-528.
35. Betz J, Bielaszewska M, Thies A, Humpf HU, Dreisewerd K, et al. (2011) Shiga toxin glycosphingolipid receptors in microvascular and macrovascular endothelial cells: differential association with membrane lipid raft microdomains. Journal of lipid research 52: 618-634.
36. Dykstra M, Cherukuri A, Sohn HW, Tzeng SJ and Pierce SK (2003) Location is everything: lipid rafts and immune cell signaling. Annual review of immunology 21: 457-481. (Pubitemid 37174538)
37. Lajoie P, Goetz JG, Dennis JW and Nabi IR (2009) Lattices, rafts, and scaffolds: domain regulation of receptor signaling at the plasma membrane. The Journal of cell biology 185: 381-385.
38. Lingwood CA, Manis A, Mahfoud R, Khan F, Binnington B, et al. (2010) New aspects of the regulation of glycosphingolipid receptor function. Chemistry and physics of lipids 163: 27-35.
39. Saito M, Mylvaganum M, Tam P, Novak A, Binnington B, et al. (2012) Structure-dependent pseudoreceptor intracellular traffic of adamantyl globotriaosyl ceramide mimics. The Journal of biological chemistry 287: 16073-16087.
40. Gallegos KM, Conrady DG, Karve SS, Gunasekera TS, Herr AB, et al. (2012) Shiga Toxin Binding to Glycolipids and Glycans. PloS one 7: e30368.
41. Ling H, Panni NS, Boodhoo A, Armstrong GD, Clark CG, et al. (2000) A mutant Shiga-like toxin IIe bound to its receptor Gb3: structure of a group II Shiga-like toxin with altered binding specificity. Structure 8: 252-264.
42. Ling H, Boodhoo A, Hazes B, Cummings MD, Armstrong GD, et al. (1998) Structure of the shiga-like toxin I B-pentamer complexed with an analogue of its receptor Gb3. Biochemistry 37: 1777-1788. (Pubitemid 28099800)
43. Soltyk AM, MacKenzie CR, Wolski VM, Hirama T, Kitov PI, et al. (2002) A mutational analysis of the globotriaosylceramide-binding sites of verotoxin VT1. The Journal of biological chemistry 277: 5351-5359. (Pubitemid 34968581)
44. Jacobson JM, Yin J, Kitov PI, Mulvey GL, Griener TP, et al. (2014) The crystal structure of Shiga toxin type 2 with bound disaccharide guides the design of a heterobifunctional toxin inhibitor. J Biol Chem 289: 885-894.
45. Kitova EN, Daneshfar R, Marcato P, Mulvey GL, Armstrong G, et al. (2005) Stability of the homopentameric B subunits of shiga toxins 1 and 2 in solution and the gas phase as revealed by nanoelectrospray fourier transform ion cyclotron resonance mass spectrometry. Journal of the American Society for Mass Spectrometry 16: 1957-1968. (Pubitemid 41642959)
46. Conrady DG, Flagler MJ, Friedmann DR, Vander Wielen BD, Kovall RA, et al. (2010) Molecular Basis of Differential B-Pentamer Stability of Shiga Toxins 1 and 2. PloS one 5: e15153.
47. Yasumura Y and Kawakita Y (1963) Studies on SV40 in tissue culture - preliminary step for cancer research in vitro. Nihon Risnsho 21: 1201-1215.
48. McGannon CM, Fuller CA and Weiss AA (2010) Different classes of antibiotics differentially influence shiga toxin production. Antimicrob Agents Chemother 54: 3790-3798.
49. Lingwood CA (1996) Role of verotoxin receptors in pathogenesis. Trends Microbiol 4: 147-153.
50. Rutjes NW, Binnington BA, Smith CR, Maloney MD and Lingwood CA (2002) Differential tissue targeting and pathogenesis of verotoxins 1 and 2 in the mouse animal model. Kidney Intl 62: 832-845. (Pubitemid 35316712)
51. Millen SH, Lewallen DM, Herr AB, Iyer SS and Weiss AA (2010) Identification and characterization of the carbohydrate ligands recognized by pertussis toxin via a glycan microarray and surface plasmon resonance. Biochemistry 49: 5954-5967.
52. Mahfoud R, Manis A, Binnington B, Ackerley C and Lingwood C (2010) A Major Fraction of Glycosphingolipids in Model and Cellular Cholesterol- containing Membranes Is Undetectable by Their Binding Proteins. J Biol Chem 285: 36049-36059.
53. Nakajima H, Kiyokawa N, Katagiri YU, Taguchi T, Suzuki T, et al. (2001) Kinetic Analysis of Binding between Shiga Toxin and Receptor Glycolipid Gb3Cer by Surface Plasmon Resonance. J Biol Chem 276: 42915-42922.
54. Watanabe M, Igai K, Matsuoka K, Miyagawa A, Watanabe T, et al. (2006) Structural analysis of the interaction between Shiga toxin B subunits and linear polymers bearing clustered globotriose residues. Infection and immunity 74: 1984-1988. (Pubitemid 43346841)